PL1699459T3 - Sposób leczenia stwardnienia rozsianego - Google Patents

Sposób leczenia stwardnienia rozsianego

Info

Publication number: PL1699459T3
Authority: PL; Poland
Prior art keywords: multiple sclerosis; meca; treatment; a3rag; apnea
Prior art date: 2003-12-29

Application number

PL04806691T

Other languages

English (en)

Inventor

Pnina Fishman

Yehuda Sara Bar

Lea Madi

Original Assignee

Can Fite Biopharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-29

Filing date

2004-12-23

Publication date

2007-12-31

2004-12-23 Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd

2007-12-31 Publication of PL1699459T3 publication Critical patent/PL1699459T3/pl

Links

201000006417 multiple sclerosis Diseases 0.000 title abstract 2
229940122614 Adenosine receptor agonist Drugs 0.000 abstract 3
239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 3
IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 abstract 1
LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 abstract 1
HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 abstract 1
101150046889 ADORA3 gene Proteins 0.000 abstract 1
208000008784 apnea Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preliminary Treatment Of Fibers (AREA)
Spinning Or Twisting Of Yarns (AREA)
Treatment Of Fiber Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Sewing Machines And Sewing (AREA)
Steroid Compounds (AREA)

PL04806691T 2003-12-29 2004-12-23 Sposób leczenia stwardnienia rozsianego PL1699459T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53271203P	2003-12-29	2003-12-29
PCT/IL2004/001160 WO2005063246A1 (en)	2003-12-29	2004-12-23	Method for treatment of multiple sclerosis
EP04806691A EP1699459B1 (en)	2003-12-29	2004-12-23	Method for treatment of multiple sclerosis

Publications (1)

Publication Number	Publication Date
PL1699459T3 true PL1699459T3 (pl)	2007-12-31

Family

ID=34738826

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04806691T PL1699459T3 (pl)	2003-12-29	2004-12-23	Sposób leczenia stwardnienia rozsianego

Country Status (10)

Country	Link
US (1)	US7465715B2 (pl)
EP (1)	EP1699459B1 (pl)
JP (1)	JP2007517019A (pl)
CN (1)	CN100423723C (pl)
AT (1)	ATE363907T1 (pl)
DE (1)	DE602004006895T2 (pl)
DK (1)	DK1699459T3 (pl)
ES (1)	ES2287804T3 (pl)
PL (1)	PL1699459T3 (pl)
WO (1)	WO2005063246A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
KR20070100261A (ko)	2004-12-02	2007-10-10	캔-파이트 바이오파마 리미티드	염증 치료법
GB0500785D0 (en) *	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
EP1983990B1 (en)	2006-01-26	2011-03-23	Government of the United States of America, Represented by the Secretary, Department of Health and Human Services	A3 adenosine receptor allosteric modulators
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
PT2322525E (pt) *	2006-04-21	2013-12-26	Novartis Ag	Derivados de purina para utilização como agonistas do recetor de adenosina a2a
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (en)	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
EP1903044A1 (en) *	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) *	2006-11-10	2009-10-07	诺瓦提斯公司	环戊烯二醇单乙酸酯衍生物
HUE034474T2 (en)	2007-03-14	2018-02-28	Can Fite Biopharma Ltd	Method for the synthesis of IB-meca
US20090088403A1 (en) *	2007-05-07	2009-04-02	Randy Blakely	A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2011010306A1 (en)	2009-07-21	2011-01-27	Ramot At Tel-Aviv University Ltd.	A3 adenosine receptor ligands for modulation of pigmentation
IL200753A (en)	2009-09-06	2015-06-30	Can Fite Biopharma Ltd	Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
JP5565784B2 (ja) *	2011-04-22	2014-08-06	国立大学法人京都大学	関節リウマチの新規遺伝因子としてのミエリン塩基性蛋白の利用
SG10201913554YA (en)	2011-12-22	2020-03-30	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
JP2015504088A (ja) *	2012-01-23	2015-02-05	キャン−ファイトバイオファーマリミテッドＣａｎ−ＦｉｔｅＢｉｏＰｈａｒｍａＬｔｄ．	肝疾患の治療
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP3445368B1 (en)	2016-04-21	2024-07-17	Astrocyte Pharmaceuticals, Inc.	Compounds and methods for treating neurological and cardiovascular conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5310732A (en)	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
WO1995002604A1 (en) *	1993-07-13	1995-01-26	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	A3 adenosine receptor agonists
WO1995011681A1 (en) *	1993-10-29	1995-05-04	Merck & Co., Inc.	Human adenosine receptor antagonists
WO1997033879A1 (en) *	1996-03-15	1997-09-18	Merck & Co., Inc.	Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
YU44900A (sh)	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) *	1998-02-24	2000-09-12	University Of Virginia	8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) *	1998-03-12	2001-10-16	University Of Virginia	Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US7160890B2 (en)	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
CZ294538B6 (cs) *	2002-12-30	2005-01-12	Ústav Experimentální Botaniky Akademie Vědčeské Re	Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující

2004
- 2004-12-23 JP JP2006546475A patent/JP2007517019A/ja not_active Withdrawn
- 2004-12-23 DK DK04806691T patent/DK1699459T3/da active
- 2004-12-23 DE DE602004006895T patent/DE602004006895T2/de not_active Expired - Fee Related
- 2004-12-23 ES ES04806691T patent/ES2287804T3/es not_active Expired - Lifetime
- 2004-12-23 AT AT04806691T patent/ATE363907T1/de not_active IP Right Cessation
- 2004-12-23 EP EP04806691A patent/EP1699459B1/en not_active Expired - Lifetime
- 2004-12-23 US US10/521,193 patent/US7465715B2/en not_active Expired - Fee Related
- 2004-12-23 CN CNB2004800393344A patent/CN100423723C/zh not_active Expired - Fee Related
- 2004-12-23 WO PCT/IL2004/001160 patent/WO2005063246A1/en not_active Ceased
- 2004-12-23 PL PL04806691T patent/PL1699459T3/pl unknown

Also Published As

Publication number	Publication date
US7465715B2 (en)	2008-12-16
DE602004006895T2 (de)	2008-01-31
CN1901915A (zh)	2007-01-24
JP2007517019A (ja)	2007-06-28
EP1699459A1 (en)	2006-09-13
ES2287804T3 (es)	2007-12-16
ATE363907T1 (de)	2007-06-15
DK1699459T3 (da)	2007-10-08
DE602004006895D1 (de)	2007-07-19
EP1699459B1 (en)	2007-06-06
CN100423723C (zh)	2008-10-08
US20060142237A1 (en)	2006-06-29
WO2005063246A1 (en)	2005-07-14

Publication	Publication Date	Title
PL1699459T3 (pl)	2007-12-31	Sposób leczenia stwardnienia rozsianego
MY146986A (en)	2012-10-15	Methods for treating interleukin-6 related diseases
LU92323I2 (fr)	2015-09-22	La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
AU2003296993A8 (en)	2004-07-09	Cyclopropyl compounds as ccr5 antagonists
WO2003063876A3 (en)	2003-11-27	Methods of treating patients suffering from movement disorders
MXPA02001306A (es)	2004-06-22	Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
EP1064966A3 (en)	2003-01-08	Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA05013200A (es)	2006-03-09	Derivados de estaurosporina para sindrome hipereosinofilico.
WO2005062898A3 (en)	2005-11-24	Enhanced absorption of modified release dosage forms
HUP0401805A2 (hu)	2004-12-28	Pulmonális betegségek kezelésére szolgáló vegyületek
EP1213031A3 (en)	2004-03-10	Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
TW200631956A (en)	2006-09-16	Azabenzoxazoles for the treatment of CNS disorders
WO2000053148A3 (en)	2000-12-14	Methods and compositions for treating erectile dysfunction
IL179206A0 (en)	2007-03-08	Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2003072572A8 (en)	2004-01-29	Beta3-adrenergic receptor agonists
EP1387685A4 (en)	2007-05-23	ANALGETIC COMPOSITION AND METHOD
WO2003093503A3 (en)	2005-02-24	Method for bioequivalence determination using expression profiling
AU2204701A (en)	2001-07-03	Formulations of adenosine a1 agonists
TWI256388B (en)	2006-06-11	Pharmaceutical combination
WO2004029025A3 (en)	2004-07-01	Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2003094957A3 (en)	2004-02-12	Methods of therapy for inducing tolerance
MX2007005525A (es)	2007-07-05	Tratamiento terapeutico de resorcion ose acelerada.
EP1064948A3 (en)	2003-01-08	Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
NO20062883L (no)	2006-08-18	Fosfodiesterase-V-inhibitorpreparater
AU2203101A (en)	2001-07-03	Formulations of adenosine a1 agonists